Investigators evaluated the therapeutic efficacy of ex vivo gene therapy targeting HSCs using a lentiviral vector to increase enzyme activity, reduce substrate accumulation, and improve astrocytosis and motor function.
[Molecular Therapy-Methods & Clinical Development]